S

SNBL USA

224 employees

Shin Nippon Biomedical Laboratories (SNBL), was founded in Kagoshima as Japan’s first contract research organization in 1957.

Investor insights

Sectors invested in

Biotechnology4
Health Care3
Medical2
Pharmaceutical2
Therapeutics2
MultiStem1
マザーズ1
再生医薬品1
バイオベンチャー1
iPS1
再生医療1
Stem cell1
Life Science1

Funding rounds participated in

$21M sweet spot round size

Most of their 6 investments are in rounds between $1.6M and $62M

Basic info

Industry

pharmaceutical manufacturing

Sectors

Biotechnology
Pharmaceutical
Bioanalysis
Specific Toxicity
Genotoxicity
Preclinical
Toxicology
DART
Efficacy Models
Ophthalmology
Translational Research
Safety Pharmacology
General Toxicity
Out-Licensing Business
CRO

Date founded

1957

Investments made

-

- raised $80M on March 1, 2021

Investors: Point72 Asset Management, Vivo Capital, RA Capital Management, L.P., Surveyor Capital, Commodore Capital, LP, Logos Global Management, LP, Aspire Capital Partners, LLC and SNBL USA

U

Undisclosed raised $1.6M on July 2, 2019

Investors: DG Daiwa Ventures - GP of DG Lab Fund, Advantage Risk Management Co Ltd (8769), DG Lab, TIS Inc. and SNBL USA

-

- raised $62M on April 24, 2019

Investors: Surveyor Capital, Lumira Ventures, Eventide Asset Management, SBI Investment, Wellington Management, RA Capital Management, L.P., Osage University Partners (OUP), Cormorant Capital and SNBL USA

(株)iPSポータル raised $12M on March 9, 2015

Investors: SMBCベンチャーキャピタル(株), Eisai Asia, Sumitomo Mitsui Banking Corporation (SMBC) Asia Pacific and SNBL USA

H

Healios K.K. raised $31M on October 8, 2013

Investors: Dainippon Sumitomo Pharma, Dogan, Inc. and SNBL USA

U

Undisclosed raised $465K on November 1, 2011

Investors: Japan Asia Investment Co., Ltd. and SNBL USA

FAQ